Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man.

Bentzen, Bo Hjorth; Bomholtz, Sofia Hammami; Simó-Vicens, Rafel; Folkersen, Lasse; Abildgaard, Lea; Speerschneider, Tobias; Muthukumarasamy, Kalai Mangai; Edvardsson, Nils; Sørensen, Ulrik S; Grunnet, Morten; Diness, Jonas Goldin.

Afiliação

Bentzen BH; Acesion Pharma, Copenhagen, Denmark.
Bomholtz SH; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Simó-Vicens R; Acesion Pharma, Copenhagen, Denmark.
Folkersen L; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Abildgaard L; Acesion Pharma, Copenhagen, Denmark.
Speerschneider T; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Muthukumarasamy KM; Institute of Biological Psychiatry, Sankt Hans Hospital, Roskilde, Denmark.
Edvardsson N; Acesion Pharma, Copenhagen, Denmark.
Sørensen US; Acesion Pharma, Copenhagen, Denmark.
Grunnet M; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Diness JG; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.